TOTAL: $2.75M
Year to Date: $73.17M
Company
(Symbol)#*
Partner
(Country)
Amt. (M) Details (Date)

Ablynx NV (Belgium; BR:ABLX) Novartis AG (Switzerland) ND For an exclusive research license under an ongoing research and development collaboration to discover and develop therapeutic Nanobodies targeting numerous diseases that are difficult to address with conventional antibodies and fragments (2/19)
 
Addex Pharmaceuticals (Switzerland; SWX:ADXN) Merck & Co. Inc. $0.25 For hitting a preclinical milestone in a Parkinson's disease collaboration and license agreement (2/25)
 
Archemix Corp.* Ophthotech Corp.* ND For Ophthotech's enrollment of the first volunteer in a Phase I study of E10030 for age-related macular degeneration (2/19)
 
Bionomics Ltd. (Australia; ASX:BNO) Genmab A/S (Denmark; CSE:GEN) $1 For completing preclinical testing on the first of eight proteins licensed to Genmab (2/19)
 
ImmunoGen Inc. (IMGN) Biogen Idec Inc. (BIIB) $1.5 For the submission of an investigational new drug application for BIIB015 (2/1)
 
Neose Technologies Inc. (NTEC) Novo Nordisk A/S (Denmark) ND For the use of Neose's GlycoPEGylation technology to develop a long-acting version of recombinant Factor VIII for hemophilia A (2/6)
 
Sunesis Pharmaceuticals Inc. (SNSS) Johnson & Johnson Pharmaceutical Research & Development LLC ND For J&J's selection of a compound targeting the Cathepsin S enzyme as a development candidate (2/20)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Private company. Currency conversions are based on exchange rates at the time of the deal.

ND = Not disclosed. ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; SWX = Swiss Stock Exchange.